New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
07:06 EDTMRK, CBRXColumbia Laboratories CEO sees Q3 revenues improving
Columbia Laboratories (CBRX) CEO stated, "The routine license renewal by Merck (MRK) Serono for one of its high-volume, high-margin markets is expected to be complete in 2H14, whereupon normal shipments will then resume at the beginning of 2015. The new license will be in place for five years, thereby restoring the predictability of this long-term revenue stream. In the interim, Merck Serono placed an order with us as part of a one-time exception during the renewal process. The order will be shipped in Q3 and benefit that quarter's revenues. In terms of the services business, we expect a sequential improvement in Q3 revenues due to successful recent business development activities and customer interest in our comprehensive suite of advanced technologies."
News For CBRX;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
05:49 EDTMRKStocks with implied volatility movement; MRK EFA
Stocks with implied volatility movement; Merck (MRK) 19, iShares MSCI EAFE Index Fund (EFA) 16 according to iVolatility.
May 26, 2015
16:01 EDTMRKOptions Update; May 26, 2015
Subscribe for More Information
06:36 EDTMRKMerck announces Simponi received CHMP positive opinion
MSD, known as Merck & Co., in the U.S. and Canada, announced that SIMPONI has received CHMP positive opinion for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein, or CRP, and/or magnetic resonance imaging evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. Once the EU commission issues their EC decision, and if approved, nr-axial SpA patients can be considered for the once-monthly subcutaneous injection with SIMPONI.
May 22, 2015
10:52 EDTMRKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:22 EDTMRKMerck receives positive CHMP opinion for Pembrolizumab in advanced melanoma
Subscribe for More Information
07:15 EDTMRKMerck receives positive CHMP opinion for KEYTRUDA in advanced melanoma
Merck announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma, as both first-line therapy and in previously treated patients. The CHMP positive opinion for KEYTRUDA, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the European Union.
May 19, 2015
07:28 EDTMRKUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:55 EDTMRKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 14, 2015
09:22 EDTMRKLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use